Joseph E. McClellan

As both the Chief Scientific Officer and Chief Technical Officer, Joe McClellan leads the company’s Research & Development (R&D) and Technical Operations (TechOps) functions, with overarching responsibility for bringing Alvotech’s biosimilars to market. He is an insightful scientist and passionate leader, overseeing R&D and TechOps operations across our sites in Iceland, Germany, Switzerland, Sweden, India and the US. He brings with him an outstanding track record in medicine development and commercialization, with over 20 years of extensive industry experience driving forward R&D programs and bringing important medicines to patients, while ensuring strategic and operational excellence.

Prior to joining Alvotech, Joe worked at Wyeth and Pfizer for 17 years and developed broad experience in all areas of biologic medicine development including biosimilars, innovator biologics, pharmaceutical science, clinical development, regulatory strategy and discovery research. During Joe’s tenure leading biosimilar development at Pfizer, the company secured major market approvals for 6 unique biosimilar molecules and submitted applications for 2 additional unique biosimilars that were subsequently approved.

Joe earned a Ph.D. degree in Chemistry, with a focus in Analytical Chemistry and Mass Spectrometry, from the University of Florida. In addition, he was a Postdoctoral Fellow in Mass Spectrometry and Analytical Biochemistry at the Boston University School of Medicine and received his MBA, with a focus on innovation and business growth in high-technology industries, from Northeastern University. He holds a Bachelor of Arts in Chemistry from the College of the Holy Cross.